Stock listing
Stuttgart:9IP1 Rocket Pharmaceuticals, Inc. Aktie
German listing (Stuttgart) of Rocket Pharmaceuticals, Inc. · home listing NASDAQ:RCKT
Follow Rocket Pharmaceuticals, Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:RCKT
$1.95 USD -0.16 (-7.6%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:RCKT
- Day range
- $1.94 – $2.18 USDNov 20, 2026
- Volume
- 2.90M sharesNov 20, 2026
- Market cap
- $214.1M USDAt the close on Nov 20, 2026 · price × 109.8M shares outstanding
- 52-week range
- $1.94 – $5.45 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $5.16M USDMedian day 1.79M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:RCKT · Home | $1.95 USD | -0.16 (-7.6%) | 2,898,098 | $2.07 | $2.175 | $1.94 | $2.11 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:RCKT · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $1.95 | -0.16 | -7.6% | $2.07 | $2.175 | $1.94 | 2,898,098 | |
| $2.11 | 0.00 | 0.0% | $2.09 | $2.215 | $2.06 | 2,491,533 | |
| $2.11 | -0.05 | -2.3% | $2.16 | $2.195 | $2.03 | 1,785,037 | |
| $2.16 | -0.14 | -6.1% | $2.28 | $2.35 | $2.15 | 1,919,496 | |
| $2.30 | -0.09 | -3.8% | $2.30 | $2.365 | $2.191 | 1,783,377 | |
| $2.39 | -0.09 | -3.6% | $2.45 | $2.46 | $2.35 | 954,292 | |
| $2.48 | +0.03 | +1.2% | $2.44 | $2.545 | $2.40 | 962,708 | |
| $2.45 | -0.08 | -3.2% | $2.50 | $2.58 | $2.405 | 1,224,137 | |
| $2.53 | +0.145 | +6.1% | $2.40 | $2.57 | $2.31 | 1,759,082 | |
| $2.385 | -0.05 | -2.1% | $2.41 | $2.51 | $2.36 | 1,425,517 | |
| $2.435 | -0.175 | -6.7% | $2.60 | $2.60 | $2.30 | 2,180,843 | |
| $2.61 | +0.10 | +4.0% | $2.60 | $2.66 | $2.475 | 1,648,666 | |
| $2.51 | +0.04 | +1.6% | $2.49 | $2.635 | $2.42 | 1,286,821 | |
| $2.47 | +0.03 | +1.2% | $2.44 | $2.495 | $2.39 | 1,818,871 | |
| $2.44 | -0.10 | -3.9% | $2.50 | $2.57 | $2.37 | 1,535,033 | |
| $2.54 | -0.04 | -1.6% | $2.58 | $2.67 | $2.50 | 1,829,544 | |
| $2.58 | +0.13 | +5.3% | $2.42 | $2.605 | $2.372 | 1,418,501 | |
| $2.45 | +0.17 | +7.5% | $2.29 | $2.52 | $2.253 | 2,054,567 | |
| $2.28 | -0.01 | -0.4% | $2.29 | $2.291 | $2.22 | 1,514,755 | |
| $2.29 | -0.02 | -0.9% | $2.27 | $2.29 | $2.17 | 1,601,100 | |
| $2.31 | +0.11 | +5.0% | $2.20 | $2.34 | $2.18 | 2,163,500 | |
| $2.20 | -0.14 | -6.0% | $2.34 | $2.385 | $2.17 | 2,022,800 | |
| $2.34 | +0.10 | +4.5% | $2.24 | $2.37 | $2.20 | 1,889,400 | |
| $2.24 | +0.06 | +2.8% | $2.18 | $2.29 | $2.165 | 1,850,300 | |
| $2.18 | -0.18 | -7.6% | $2.36 | $2.36 | $2.17 | 1,966,800 | |
| $2.36 | +0.15 | +6.8% | $2.22 | $2.395 | $2.207 | 1,878,200 | |
| $2.21 | -0.09 | -3.9% | $2.26 | $2.295 | $2.18 | 2,009,400 | |
| $2.30 | -0.18 | -7.3% | $2.47 | $2.55 | $2.26 | 3,891,300 | |
| $2.48 | -0.08 | -3.1% | $2.54 | $2.595 | $2.46 | 2,302,700 | |
| $2.56 | -0.07 | -2.7% | $2.59 | $2.688 | $2.54 | 3,369,700 | |
| $2.63 | +0.095 | +3.7% | $2.78 | $2.78 | $2.52 | 3,455,900 | |
| $2.535 | +0.055 | +2.2% | $2.45 | $2.64 | $2.42 | 2,808,500 | |
| $2.48 | -0.13 | -5.0% | $2.61 | $2.62 | $2.46 | 1,788,300 | |
| $2.61 | +0.05 | +2.0% | $2.59 | $2.63 | $2.50 | 1,658,500 | |
| $2.56 | -0.03 | -1.2% | $2.64 | $2.66 | $2.53 | 1,818,400 | |
| $2.59 | -0.04 | -1.5% | $2.62 | $2.745 | $2.58 | 2,091,900 | |
| $2.63 | +0.04 | +1.5% | $2.62 | $2.73 | $2.55 | 2,526,800 | |
| $2.59 | -0.02 | -0.8% | $2.63 | $2.646 | $2.56 | 1,153,100 | |
| $2.61 | +0.015 | +0.6% | $2.57 | $2.62 | $2.51 | 2,074,000 | |
| $2.595 | -0.095 | -3.5% | $2.80 | $2.80 | $2.57 | 2,626,700 | |
| $2.69 | -0.33 | -10.9% | $3.00 | $3.025 | $2.66 | 4,382,300 | |
| $3.02 | -0.33 | -9.9% | $3.33 | $3.335 | $2.953 | 2,777,400 | |
| $3.35 | +0.08 | +2.4% | $3.29 | $3.41 | $3.28 | 1,072,800 | |
| $3.27 | -0.10 | -3.0% | $3.40 | $3.405 | $3.265 | 1,355,300 | |
| $3.37 | -0.13 | -3.7% | $3.47 | $3.56 | $3.35 | 1,597,900 | |
| $3.50 | +0.02 | +0.6% | $3.59 | $3.755 | $3.48 | 1,858,400 | |
| $3.48 | +0.07 | +2.1% | $3.565 | $3.57 | $3.40 | 2,644,200 | |
| $3.41 | -0.02 | -0.6% | $3.65 | $3.685 | $3.21 | 3,660,100 | |
| $3.43 | +0.08 | +2.4% | $3.29 | $3.475 | $3.29 | 1,293,400 | |
| $3.35 | -0.13 | -3.7% | $3.52 | $3.52 | $3.25 | 1,655,900 | |
| $3.48 | -0.15 | -4.1% | $3.62 | $3.63 | $3.44 | 1,185,400 | |
| $3.63 | -0.08 | -2.2% | $3.67 | $3.755 | $3.62 | 871,400 | |
| $3.71 | -0.15 | -3.9% | $3.78 | $3.782 | $3.68 | 754,700 | |
| $3.86 | +0.07 | +1.8% | $3.75 | $3.88 | $3.73 | 888,500 | |
| $3.79 | -0.07 | -1.8% | $3.90 | $3.915 | $3.69 | 1,070,300 | |
| $3.86 | +0.13 | +3.5% | $3.71 | $3.955 | $3.71 | 1,162,500 | |
| $3.73 | +0.01 | +0.3% | $3.72 | $3.805 | $3.674 | 948,700 | |
| $3.72 | -0.14 | -3.6% | $3.77 | $3.80 | $3.636 | 1,601,600 | |
| $3.86 | +0.24 | +6.6% | $3.61 | $3.99 | $3.53 | 3,454,300 | |
| $3.62 | -0.04 | -1.1% | $3.63 | $3.76 | $3.59 | 1,258,500 | |
| $3.66 | -0.12 | -3.2% | $3.73 | $3.73 | $3.58 | 1,120,200 | |
| $3.78 | +0.25 | +7.1% | $3.54 | $3.81 | $3.536 | 2,201,500 | |
| $3.53 | +0.02 | +0.6% | $3.53 | $3.55 | $3.375 | 913,300 | |
| $3.51 | +0.03 | +0.9% | $3.52 | $3.605 | $3.48 | 939,800 | |
| $3.48 | -0.17 | -4.7% | $3.60 | $3.659 | $3.43 | 1,111,200 |
Splits
1 split · NASDAQ:RCKT · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-4 | Consolidation |
- Ticker
- Stuttgart:9IP1
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Stuttgart
- Currency
- EUR
What changed lately
Latest news release · Nov 12, 2026
Rocket Pharmaceuticals Reports Third Quarter 2026 Financial Results and Highlights Recent Progress
Latest deck · November 2026
Investor Presentation (November 2026)
Investor deck · 36 slides
Latest news
Rocket Pharmaceuticals Reports Third Quarter 2026 Financial Results and Highlights Recent Progress
Nov 12, 2026
Closed $2.30 (-3.8%) on Nov 13, 2026
Rocket Pharmaceuticals to Participate in Chardan’s 10th Annual Healthcare Conference
Oct 15, 2026
Closed $2.36 (+6.8%) on Oct 15, 2026
Rocket Pharmaceuticals Highlights FDA-Aligned Pivotal Phase 2 Trial and Updated Clinical Findings for RP-A501 Following Danon Disease Investor Webinar
Oct 7, 2026
Closed $2.54 (+2.2%) on Oct 7, 2026
Rocket Pharmaceuticals Secures Strategic Credit Facility for Up to $150 Million from Hercules Capital
Oct 6, 2026
Closed $2.54 (+2.2%) on Oct 7, 2026
Rocket Pharmaceuticals Announces FDA Alignment on Path to Complete Pivotal Phase 2 Trial of RP-A501 in Danon Disease
Sep 15, 2026
Closed $3.41 (-0.6%) on Sep 15, 2026
Rocket Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Progress
Aug 10, 2026
Closed $3.50 (-3.8%) on Aug 11, 2026
Rocket Pharmaceuticals Announces Positive Clinical Safety Update from Initial Three Patients Treated with RP-A501 Under Modified Phase 2 Protocol for Danon Disease
Aug 3, 2026
Closed $3.41 (+9.6%) on Aug 3, 2026
Rocket Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $180 Million
Jun 12, 2026
Closed $2.75 (+3.4%) on Jun 12, 2026
Rocket Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Progress
May 7, 2026
Closed $3.63 (-1.1%) on May 8, 2026
Rocket Pharmaceuticals Announces $180 Million Sale of Priority Review Voucher
Apr 28, 2026
Closed $3.43 (-1.7%) on Apr 28, 2026
Rocket Pharmaceuticals, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 15 in the last 12 months · 183 in all · newest Nov 12, 2026 · oldest 2019
- Calls
- 1 call with a replay · 1 with a transcript · latest Aug 9, 2021
- Decks
- 44 decks · latest November 2026
Where Rocket Pharmaceuticals, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:RCKT · Home listing | NASDAQ | United States | USD |
| LS Exchange:A2JA9Q | LS Exchange | Germany | EUR |
| gettex:9IP1 | gettex | Germany | EUR |
| Lang & Schwarz:A2JA9Q | Lang & Schwarz | Germany | EUR |
| BOATS:RCKT | BOATS | United States | USD |
| Tradegate:9IP1 | Tradegate | Germany | EUR |
| Dusseldorf:9IP1 | Dusseldorf | Germany | EUR |
| Frankfurt:9IP1 | Frankfurt | Germany | EUR |
| Hamburg:9IP1 | Hamburg | Germany | EUR |
| Munich:9IP1 | Munich | Germany | EUR |
| Stuttgart:9IP1 · This page | Stuttgart | Germany | EUR |
Valuation
Price/book 0.7× against a median of 1.6×: 2nd lowest of 10 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$25.02M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.7×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.1×
- Beta vs S&P 500
- 1.72
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Rocket Pharmaceuticals, Inc. · NASDAQ:RCKT | US$214.1M | −US$25.02M | n/a | n/a | n/a | 0.7× | n/a | 0.1× | 1.72 |
| Allogene Therapeutics, Inc. · NASDAQ:ALLO | US$217.5M | −US$7.44M | n/a | −1.6× | n/a | 0.6× | n/a | 0.2× | 1.93 |
| ProKidney Corp. · NASDAQ:PROK | US$217.3M | US$77.56M | n/a | 100× | n/a | n/a | n/a | n/a | 1.61 |
| Pyxis Oncology, Inc. · NASDAQ:PYXS | US$216.5M | US$160.9M | n/a | n/a | n/a | 5.2× | n/a | 0.0× | 0.89 |
| Oryzon Genomics SA · BME:ORY | US$216.4M | US$206.7M | n/a | n/a | n/a | 1.6× | n/a | 0.1× | n/a |
| Transgene SA · EURONEXT:TNG | US$212.2M | US$112.7M | n/a | 750× | n/a | 1.8× | n/a | 0.0× | n/a |
| Arcturus Therapeutics Holdings Inc. · NASDAQ:ARCT | US$211.8M | US$45.18M | n/a | 1.5× | n/a | 1.3× | −285.9% | 0.1× | 2.01 |
| Century Therapeutics, Inc. · NASDAQ:IPSC | US$211.6M | US$131.9M | n/a | n/a | n/a | 1.0× | n/a | 0.2× | 2.35 |
| Orum Therapeutics, Inc. · KRX:475830 | US$211.2M | US$24.07M | 15.4× | n/a | n/a | 1.5× | n/a | 0.0× | n/a |
| GemVax & KAEL Co Ltd · KRX:082270 | US$211.0M | US$206.2M | n/a | 3.3× | 21.2× | 3.8× | −14.4% | 0.4× | n/a |
| AnnJi Pharmaceutical Co., Ltd. · TPEX:7754 | US$209.9M | US$195.9M | n/a | 855× | n/a | 16.5× | n/a | 0.0× | n/a |
| Median of the others | US$212.0M | US$122.3M | 15.4× | 51.7× | 21.2× | 1.6× | −150.1% | 0.1× | 1.93 |
Forecasts
6 strong buy · 1 buy · 6 hold · 1 sell · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.
- Price target
- 8.58 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.11 · 4 analysts
- Revenue, year to Dec 2026
- 935.2K · 11 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Gaurav Shah | Chief Executive Officer |
Board
| Director | Role |
|---|---|
| Peter Fong | Chairman of the Board |
| Carsten Boess | Independent Director |
| David Southwell | Director |
| Fady Malik | Independent Director |
| Gaurav Shah | Chief Executive Officer |
| Mikael Dolsten | Director |
| Roderick Wong | Director |
Events
Calls
| Call | When | Status |
|---|---|---|
| Rocket Pharmaceuticals (NASDAQ:RCKT) Q2 2021 Earnings Call | Mon, Aug 09, 2021 · 4:30 PM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 12, 2026 · After close | −3.8% |
| Q2 2026 | Aug 10, 2026 · After close | −3.9% |
| Q1 2026 | May 7, 2026 · After close | −1.1% |
| Q4 2025 | Feb 26, 2026 | +15.7% |
| Q3 2025 | Nov 6, 2025 · After close | −1.9% |
| Q2 2025 | Aug 7, 2025 | −5.3% |
| Q1 2025 | May 8, 2025 · After close | −0.7% |
| Q4 2024 | Feb 24, 2025 · Before open | −4.0% |
| Q3 2024 | Nov 7, 2024 · After close | +1.2% |
| Q2 2024 | Aug 5, 2024 · After close | +0.8% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 6, 2024 · After close | +0.7% |
| Q4 2023 | Feb 25, 2024 · After close | +1.7% |
| Q3 2023 | Nov 7, 2023 · After close | −4.4% |
| Q2 2023 | Aug 9, 2023 · After close | −1.1% |
| Q1 2023 | May 4, 2023 · After close | +12.4% |
| Q4 2022 | Feb 28, 2023 · After close | +5.4% |
| Q3 2022 | Nov 3, 2022 · After close | −4.3% |
| Q2 2022 | Aug 8, 2022 · After close | +2.5% |
| Q1 2022 | May 5, 2022 · After close | −5.5% |
| Q4 2021 | Feb 24, 2022 · Before open | +4.0% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (November 2026) | Investor deck | 36 slides | November 2026 |
| Corporate Update (October 2026) | Corporate update | 23 slides | Oct 6, 2026 |
| Investor Presentation (August 2026) | Investor deck | 34 slides | August 2026 |
| Technical Presentation (May 2025) | Technical | 19 slides | May 15, 2025 |
| Technical Presentation (November 2024) | Technical | 15 slides | Nov 18, 2024 |
| Corporate Update (September 2023) | Corporate update | 25 slides | Sep 12, 2023 |
| 41st Annual J.P. Morgan Healthcare Conference (January 2023) | Conference | 45 slides | Jan 9, 2023 |
| Investor Presentation (December 2022) | Investor deck | 60 slides | Dec 12, 2022 |
| 64th Annual Meeting of the American Society of Hematology (ASH) 2022 | Conference | 16 slides | December 2022 |
| 64th Annual Meeting of the American Society of Hematology (ASH) 2022 | Conference | 15 slides | December 2022 |
All 44 decks
Financings
| Raise | Date |
|---|---|
| Term loan credit facility with warrants Tranche closed: US$35M raised · warrants to purchase shares of Rocket's common stock · LifeSci Capital +1 Dealers: LifeSci Capital, PJT Buyers: Hercules Capital, Inc. (credit facility for up to $150 million; $35 million funded at closing) Use of proceeds: Support the pivotal Phase 2 study of RP-A501 for Danon disease and advance the broader cardiovascular pipeline | Oct 6, 2026 |
| Public offering of shares of common stock Made bigger: US$165M · US$12.5 a share · Morgan Stanley +3 Dealers: Morgan Stanley (co-lead), Leerink Partners (co-lead), Cantor (co-lead), LifeSci Capital | Dec 11, 2024 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Went public as INOTEK PHARMACEUTICALS CORP. Priced at US$6.00 a share on Feb 17, 2015.
- Price
- US$6.00 a share
- Shares offered
- 6,667,000 shares of common stock
- Offering size
- US$40 million
- Underwriters
- Cowen and Company, Piper Jaffray, Canaccord Genuity, Nomura · In the order on the cover
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Aug 29, 2014 |
| Filed publicly | Nov 5, 2014 |
| Amended 5 times | Newest Feb 17, 2015 |
| Shares registered with an exchange | Feb 2, 2015 |
| Declared effective by the SEC | Feb 17, 2015 |
| Final prospectus, with the price | Feb 19, 2015 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Feb 19, 2015 |
| 424B4 · Prospectus | Feb 19, 2015 |
| FWP · Free writing prospectus | Feb 18, 2015 |
| EFFECT · Notice that a registration is effective | Feb 17, 2015 |
| S-1/A · Registration statement, amended | Feb 17, 2015 |
| CORRESP · Letter to the SEC | Feb 17, 2015 |
| CORRESP · Letter to the SEC | Feb 17, 2015 |
| FWP · Free writing prospectus | Feb 17, 2015 |
| S-1/A · Registration statement, amended | Feb 17, 2015 |
| CORRESP · Letter to the SEC | Feb 9, 2015 |
All 30 filings
| Filing | Filed |
|---|---|
| CORRESP · Letter to the SEC | Feb 9, 2015 |
| CERTNAS · Nasdaq's certificate of listing | Feb 4, 2015 |
| CORRESP · Letter to the SEC | Feb 3, 2015 |
| CORRESP · Letter to the SEC | Feb 3, 2015 |
| 8-A12B · Registration of shares for listing on an exchange | Feb 2, 2015 |
| S-1/A · Registration statement, amended | Jan 22, 2015 |
| S-1/A · Registration statement, amended | Jan 14, 2015 |
| CORRESP · Letter to the SEC | Nov 26, 2014 |
| CORRESP · Letter to the SEC | Nov 26, 2014 |
| UPLOAD · Letter from the SEC | Nov 26, 2014 |
| CORRESP · Letter to the SEC | Nov 21, 2014 |
| CORRESP · Letter to the SEC | Nov 21, 2014 |
| S-1/A · Registration statement, amended | Nov 21, 2014 |
| UPLOAD · Letter from the SEC | Nov 18, 2014 |
| S-1 · Registration statement | Nov 5, 2014 |
| CORRESP · Letter to the SEC | Nov 4, 2014 |
| UPLOAD · Letter from the SEC | Oct 14, 2014 |
| DRS/A · Draft registration statement, amended | Sep 29, 2014 |
| UPLOAD · Letter from the SEC | Sep 25, 2014 |
| DRS · Draft registration statement | Aug 29, 2014 |
Open IPO · From the cover of the final prospectus (424B4) filed Feb 19, 2015
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of revenue | 11.0M | 9.38M | 7.10M | 6.27M | 5.37M | 1.15M | 426.0K | 330.0K | 204.0K | 169.0K |
| Gross profit | -11.0M | -9.38M | -7.10M | -6.27M | -5.37M | -1.15M | -426.0K | -330.0K | -204.0K | -169.0K |
| Research and development | 142.0M | 171.2M | 186.3M | 165.6M | 125.5M | 105.4M | 57.9M | 53.3M | 14.9M | 5.99M |
| Selling, general and administrative | 86.5M | 102.0M | 73.3M | 58.8M | 41.8M | 27.9M | 17.5M | 17.9M | 12.5M | 9.89M |
| Operating income | -231.7M | -273.2M | -259.7M | -224.3M | -167.2M | -134.3M | -76.2M | -71.2M | -19.8M | -7.57M |
| Depreciation and amortization | 8.90M | 7.20M | 4.90M | 3.90M | 3.20M | 1.15M | 426.0K | 330.0K | 204.0K | 67.0K |
| EBITDA | -222.8M | -266.0M | -254.8M | -220.4M | -164.0M | -133.2M | -75.7M | -70.8M | -19.6M | -7.51M |
| Interest expense | 1.89M | 1.89M | 1.88M | 1.86M | 2.98M | 6.97M | 5.96M | 6.04M | 0 | 0 |
| Income before tax | -223.1M | -258.7M | -245.6M | -221.9M | -169.1M | -139.7M | -77.3M | -74.5M | -29.5M | -42.9M |
| Income tax | 0 | 0 | 0 | -2.48M | 516.0K | 6.97M | 5.96M | 2.68M | 819.0K | 443.0K |
| Net income | -223.1M | -258.7M | -245.6M | -221.9M | -169.1M | -139.7M | -77.3M | -74.5M | -19.6M | -7.57M |
| Earnings per share, basic | -2.01 | -2.73 | -2.92 | -3.26 | -2.67 | -2.52 | -1.58 | -1.89 | -2.88 | -1.11 |
| Earnings per share, diluted | -2.01 | -2.73 | -2.92 | -3.26 | -2.67 | -2.52 | -1.58 | -1.89 | -2.88 | -1.11 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 77.6M | 163.6M | 55.9M | 140.5M | 232.7M | 297.1M | 185.4M | 111.4M | 18.1M | 29.8M |
| Short-term investments | 111.4M | 208.7M | 317.3M | 215.9M | 156.0M | 185.6M | 118.7M | 94.4M | 0 | 96.7M |
| Inventory | 0 | 0 | 0 | |||||||
| Current assets | 192.7M | 378.2M | 378.2M | 364.1M | 392.1M | 487.3M | 307.8M | 209.1M | 19.0M | 128.3M |
| Property, plant and equipment | 28.2M | 36.8M | 39.2M | 29.0M | 22.3M | 19.2M | 29.5M | 2.03M | 985.0K | 1.13M |
| Goodwill | 39.2M | 39.2M | 39.2M | 39.2M | 30.8M | 30.8M | 30.8M | 30.8M | 0 | 0 |
| Total assets | 330.4M | 527.7M | 566.3M | 551.8M | 497.0M | 590.8M | 372.1M | 251.3M | 20.1M | 129.6M |
| Accounts payable | 1.63M | 1.77K | 36.7M | 482 | 835 | 340 | 589 | 0 | 1.59M | |
| Current liabilities | 30.2M | 40.7M | 48.5M | 39.2M | 22.2M | 32.6M | 18.3M | 15.4M | 4.52M | 7.04M |
| Long-term debt | 35.1M | 45.0M | 41.4M | 49.5M | 49.0M | |||||
| Total debt | 0 | 25.5M | 25.0M | 22.9M | 22.6M | 61.7M | 47.4M | 41.4M | 49.5M | 49.0M |
| Total liabilities | 53.2M | 64.5M | 73.8M | 62.1M | 42.3M | 87.3M | 64.8M | 57.3M | 4.63M | 56.5M |
| Shareholders' equity | 277.2M | 463.2M | 492.6M | 489.7M | 454.7M | 503.5M | 307.3M | 194.0M | 15.5M | 8.37M |
| Shares outstanding | 108.3M | 106.5M | 90.3M | 79.1M | 64.5M | 61.0M | 54.8M | 45.1M | 6.80M | 6.75M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -190.0M | -209.7M | -194.9M | -178.1M | -121.2M | -74.6M | -64.7M | -53.8M | -16.0M | -5.50M |
| Capital spending | -440.0K | -5.86M | -16.4M | -8.36M | -7.62M | -20.6M | -23.3M | -1.45M | -760.0K | -335.0K |
| Free cash flow | -190.5M | -215.6M | -211.4M | -186.5M | -128.8M | -95.2M | -87.9M | -55.2M | -16.7M | -5.84M |
| Cash from investing | 103.8M | 131.7M | -98.1M | -69.3M | 18.9M | -96.6M | -39.0M | -5.27M | -760.0K | -335.0K |
| Cash from financing | 148.0K | 185.7M | 208.4M | 155.3M | 37.7M | 283.0M | 177.8M | 153.5M | 25.4M | 16.0K |
| Dividends paid | -172.0K | -5.56M | 0 | -155.0K | ||||||
| Share buybacks | -67.0K | 0 | 0 | -47.0K | 0 | -72.0K | 0 | 0 | 0 | 0 |
| Change in cash | -86.1M | 107.7M | -84.6M | -92.2M | -64.6M | 111.8M | 74.1M | 94.4M | 48.9M | -50.2M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 20, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 18, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 18, 2026 | Other filings | SEC |
| 4 · Change in ownership | Nov 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 17, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 13, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 13, 2026 | Other filings | SEC |
| 4 · Change in ownership | Nov 12, 2026 | Insider trade | SEC |
| 8-K · Current report | Nov 12, 2026 | Results | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Nov 12, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | Nov 9, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 9, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 9, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 5, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 30, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Oct 6, 2026 | Material contract | SEC |
| 4 · Change in ownership | Sep 15, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 15, 2026 | Other filings | SEC |
| 8-K · Current report | Sep 15, 2026 | Current report | SEC |
| 144 · Notice of proposed sale | Sep 14, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 11, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 11, 2026 | Other filings | SEC |
| 25-NSE | Sep 2, 2026 | Other filings | SEC |
| 8-K · Current report | Aug 27, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Aug 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 20, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 18, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 18, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 18, 2026 | Other filings | SEC |
| 4 · Change in ownership | Aug 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 13, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 13, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 13, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 11, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 11, 2026 | Other filings | SEC |
| 8-K · Current report | Aug 10, 2026 | Results | SEC |
| 10-Q · Quarterly report | Aug 10, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | Aug 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 5, 2026 | Insider trade | SEC |
| 8-K · Current report | Aug 3, 2026 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 31, 2026 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | Jul 14, 2026 | Offer document | SEC |
| 3 · Initial statement of ownership | Jul 8, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 7, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jul 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 6, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 30, 2026 | Management or board change | SEC |
| 8-K · Current report | Jun 12, 2026 | Acquisition or disposal | SEC |
| SC TO-I/A | May 28, 2026 | Acquisition or disposal | SEC |
| 4 · Change in ownership | May 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 21, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 21, 2026 | Other filings | SEC |
| 8-K · Current report | May 21, 2026 | Meeting outcome | SEC |
| 144 · Notice of proposed sale | May 19, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 19, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 19, 2026 | Other filings | SEC |
| 4 · Change in ownership | May 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 13, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 13, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 13, 2026 | Other filings | SEC |
| 4 · Change in ownership | May 11, 2026 | Insider trade | SEC |
| 8-K · Current report | May 7, 2026 | Results | SEC |
| 10-Q · Quarterly report | May 7, 2026 | Quarterly report | SEC |
| 144 · Notice of proposed sale | May 7, 2026 | Other filings | SEC |
| 8-K · Current report | Apr 28, 2026 | Material contract | SEC |
| SC TO-I | Apr 27, 2026 | Acquisition or disposal | SEC |
| ARS · Annual report to shareholders | Apr 6, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 6, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 6, 2026 | Meeting notice | SEC |
| SC TO-C | Apr 3, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 27, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Mar 27, 2026 | Current report | SEC |
| PRE 14A · Preliminary proxy statement | Mar 24, 2026 | Meeting notice | SEC |
| EFFECT · Notice that a registration is effective | Mar 11, 2026 | Other filings | SEC |
| 8-K · Current report | Mar 10, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Mar 10, 2026 | Offer document | SEC |
| CORRESP · Letter to the SEC | Mar 6, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Mar 6, 2026 | Other filings | SEC |
| S-3 · Registration statement | Mar 2, 2026 | Offer document | SEC |
| 8-K · Current report | Feb 26, 2026 | Results | SEC |
| 10-K · Annual report | Feb 26, 2026 | Annual report | SEC |
| 4 · Change in ownership | Feb 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 18, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 18, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 18, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 13, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 13, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 13, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 13, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 13, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 13, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 30, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 20, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 18, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 18, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 18, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 18, 2025 | Other filings | SEC |
| 4 · Change in ownership | Nov 10, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 6, 2025 | Results | SEC |
| 4 · Change in ownership | Oct 16, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 14, 2025 | Other filings | SEC |
| 8-K · Current report | Oct 14, 2025 | Current report | SEC |
| 4 · Change in ownership | Oct 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 3, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 3, 2025 | Insider trade | SEC |
| 8-K · Current report | Oct 3, 2025 | Management or board change | SEC |
| 8-K · Current report | Oct 3, 2025 | Current report | SEC |
| 8-K · Current report | Sep 29, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Sep 23, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 22, 2025 | Insider trade | SEC |
| 8-K · Current report | Sep 17, 2025 | Material contract | SEC |
| 4 · Change in ownership | Sep 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 27, 2025 | Insider trade | SEC |
| 8-K · Current report | Aug 25, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Aug 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 20, 2025 | Insider trade | SEC |
| 8-K · Current report | Aug 20, 2025 | Current report | SEC |
| 144 · Notice of proposed sale | Aug 19, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 19, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 19, 2025 | Other filings | SEC |
| 4 · Change in ownership | Aug 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 18, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 18, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 18, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 18, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 14, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 14, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 14, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 7, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 7, 2025 | Results | SEC |
| 4 · Change in ownership | Aug 6, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 4, 2025 | Insider trade | SEC |
| 8-K · Current report | Jul 24, 2025 | Current report | SEC |
| 8-K · Current report | Jul 23, 2025 | Current report | SEC |
| 4 · Change in ownership | Jul 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 18, 2025 | Insider trade | SEC |
| 8-K · Current report | Jul 17, 2025 | Current report | SEC |
| 8-K · Current report | Jul 11, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Jul 8, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 3, 2025 | Other filings | SEC |
| 8-K · Current report | Jun 18, 2025 | Meeting outcome | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jun 5, 2025 | Big-stake notice | SEC |
| 8-K · Current report | May 27, 2025 | Current report | SEC |
| 4 · Change in ownership | May 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 20, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | May 20, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | May 20, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | May 20, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | May 20, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | May 16, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | May 16, 2025 | Other filings | SEC |
This page holds 200 of 982 filings. Open Filings
Cap table
Built by 6ix from Rocket Pharmaceuticals, Inc.’s releases · as of Oct 6, 2026
- Common shares
- 109,774,597
- Fully diluted
- 109,774,597
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 109,774,597 |
Warrants and options
| Lot |
|---|
| Warrants · expiry not stated |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 109,774,597 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Patrick Machado Other companies: Alumis Inc. (Independent Board Member · Since at least Jun 27, 2024); Xenon Pharmaceuticals Inc. (Director · Since at least Nov 5, 2020); Arcus Biosciences, Inc. (Board Member · Since at least Dec 10, 2019); Adverum Biotechnologies Inc (Director · Since at least Mar 14, 2017); Turnstone Biologics Corp. (Director · Jul 20, 2023 – Jul 20, 2023 · Past); Acelyrin, Inc. (Director · May 4, 2023 – May 21, 2025 · Past); Roivant Sciences Ltd. (Director · Oct 1, 2021 – Oct 1, 2021 · Past); Principia Biopharma Inc (Director · Jun 11, 2019 – Sep 28, 2020 · Past); Turning Point Therapeutics Inc (Director · May 13, 2019 – Aug 17, 2022 · Past); Endocyte Inc (Director · Feb 27, 2018 – Dec 21, 2018 · Past); Sio Gene Therapies Inc (Director · Jul 17, 2017 – Jul 17, 2017 · Past); Scynexis, Inc. (Director · Sep 24, 2015 – Jan 2, 2019 · Past); Chimerix Inc (Director · Jun 20, 2014 – Jun 9, 2023 · Past); Medivation Inc (Director · Jun 5, 2007 – Sep 28, 2016 · Past) | Director · Aug 17, 2016 – Jun 20, 2017 · Past |
| Pedro P Granadillo Other companies: Orchestra BioMed Holdings, Inc. (Director · Aug 3, 2020 – Aug 3, 2020 · Past); Immunovant, Inc. (Director · May 9, 2019 – May 9, 2019 · Past); NPS Pharmaceuticals Inc (Director · Nov 17, 2010 – Feb 21, 2015 · Past); Dendreon Corp (Director · Oct 7, 2009 – Jan 3, 2014 · Past); Capricor Therapeutics, Inc. (Director · Oct 16, 2007 – May 10, 2011 · Past); Haemonetics Corporation (Director · May 5, 2006 – Nov 8, 2018 · Past); First Indiana Corp (Director · Jan 3, 2006 – Jan 2, 2008 · Past) | Director · Since at least Jan 4, 2018 |
| Timothy J Barberich Other companies: TScan Therapeutics, Inc. (Director · Jul 15, 2021 – Dec 18, 2023 · Past); Korro Bio, Inc. (Director · Oct 2, 2019 – Aug 17, 2022 · Past); Eledon Pharmaceuticals, Inc. (Director · Sep 16, 2014 – Jun 15, 2016 · Past); Verastem, Inc. (Director · Mar 10, 2014 – Jun 28, 2021 · Past); HeartWare International Inc (Director · Apr 29, 2008 – Aug 23, 2016 · Past); Biosphere Medical Inc (Director · May 10, 2006 – Sep 10, 2010 · Past); Sepracor Inc (Director · Mar 16, 2006 – Oct 20, 2009 · Past) | Director · Sep 28, 2016 – Jun 20, 2017 · Past |
| Argeris N Karabelas Other companies: Regenxbio Inc. (Director · Since at least Sep 16, 2015); Bausch Health Companies Inc. (Director · Jun 14, 2016 – Jun 24, 2022 · Past); Human Genome Sciences Inc (Director · Apr 27, 2006 – Jul 30, 2012 · Past); Vanda Pharmaceuticals Inc. (Director · Apr 12, 2006 – Jun 16, 2011 · Past); Nitromed Inc (Director · Mar 20, 2006 – Apr 24, 2009 · Past) | Director · Feb 17, 2015 – Jun 24, 2015 · Past |
| Carsten Boess Other companies: Atrium Therapeutics, Inc. (Director · Since at least Nov 10, 2025); Avidity Biosciences, Inc (Director · Since at least Jun 11, 2020); Orchestra BioMed Holdings, Inc. (Director · Aug 3, 2020 – Aug 3, 2020 · Past); Synageva BioPharma Corp (SVP, Chief Financial Officer · Nov 2, 2011 – Jun 22, 2015 · Past); Insulet Corporation (Vice President, International · May 14, 2007 – Apr 25, 2011 · Past) | Director · Since at least Jan 11, 2016 |
| Keith Woods Other companies: Neurogene Inc. (Director · Since at least Jun 12, 2025); Scholar Rock Holding Corporation (Chief Operating Officer · Since at least Apr 27, 2025); TScan Therapeutics, Inc. (Director · Since at least Dec 6, 2023); X4 Pharmaceuticals, Inc. (Director · Since at least Oct 16, 2023) | Director · Dec 7, 2023 – Jun 13, 2024 · Past |
| Mikael Dolsten Other companies: Apellis Pharmaceuticals, Inc. (Director · Since at least Feb 27, 2026); Agilent Technologies, Inc. (Director · Since at least Sep 21, 2021); Karyopharm Therapeutics Inc. (Director · Mar 31, 2015 – May 21, 2021 · Past); Pfizer, Inc. (President R&D · Oct 16, 2009 – Sep 12, 2024 · Past) | Director · Since at least Sep 5, 2024 |
| Gary Phillips Other companies: Aldeyra Therapeutics, Inc. (Director · Since at least May 1, 2014); Egalet Corporation (Director · Jun 18, 2019 – May 20, 2020 · Past); Mallinckrodt Inc (Exec. VP & Chief Strategy Ofcr · Oct 21, 2013 – Jan 3, 2018 · Past) | Director · Oct 13, 2015 – Jun 20, 2017 · Past |
| Martin Vogelbaum Other companies: NephroGenex Inc (Director · Feb 10, 2014 – May 15, 2014 · Past); Tvardi Therapeutics, Inc. (Director · Jan 30, 2014 – Jun 4, 2024 · Past); MiddleBrook Pharmaceuticals Inc (Director · Apr 20, 2007 – Jun 23, 2009 · Past) | Director · Feb 17, 2015 – Jun 24, 2015 · Past |
| Kamran Alam Other companies: Taysha Gene Therapies, Inc. (Chief Financial Officer · Since at least Sep 23, 2020); Neurogene Inc. (CFO, Vice President Finance · Mar 9, 2018 – Aug 7, 2018 · Past) | SVP - Finance & PFO · Oct 28, 2019 – Feb 6, 2020 · Past |
All 35 people
| Person | Seat |
|---|---|
| Naveen Yalamanchi Other companies: Orchestra BioMed Holdings, Inc. (Chief Financial Officer, Director · Aug 3, 2020 – Aug 3, 2020 · Past); Immunovant, Inc. (Vice President and CFO, Director · May 9, 2019 – May 9, 2019 · Past) | Director · Jan 4, 2018 – Jun 13, 2024 · Past |
| Syed Ali-aamir Rizvi Other companies: Poseida Therapeutics Inc (Chief Medical Officer · Apr 1, 2024 – Jan 8, 2025 · Past); Caribou Biosciences, Inc. (Chief Medical Officer · Jan 18, 2022 – Feb 21, 2023 · Past) | Chief Medical Officer · Since at least Sep 15, 2025 |
| David P. Southwell Other companies: PTC Therapeutics, Inc. (Director · Since at least Sep 9, 2025) | Director · Since at least Jun 18, 2025 |
| Elisabeth Björk Other companies: Pharvaris N.V. (Director · Since at least Mar 18, 2026) | Director · Since at least Apr 20, 2020 |
| Fady I. Malik Other companies: Cytokinetics, Incorporated (EVP, Research & Development · Since at least Jun 1, 2012) | Independent Director · Since at least Mar 10, 2022 |
| Gaurav Shah Other companies: Tourmaline Bio Inc. (Director · May 6, 2021 – Jun 13, 2023 · Past) | Chief Executive Officer · Since at least Jan 4, 2018 |
| Gotham Makker Other companies: Immunovant, Inc. (Director · May 9, 2019 – May 9, 2019 · Past) | Director · Since at least Jan 4, 2018 |
| Jonathan David Schwartz Other companies: Tabula Rasa HealthCare Inc (Director · Sep 13, 2022 – Nov 3, 2023 · Past) | See Remarks · Since at least Mar 30, 2022 |
| Roderick Wong Other companies: Allurion Technologies, Inc. (Director · Since at least Apr 16, 2025) | Director · Since at least Jun 13, 2024 |
| Aaron Ondrey | Chief Financial Officer · Since at least Mar 25, 2024 |
| Brian Batchelder | See Remarks · Jan 4, 2018 – Jan 4, 2018 · Past |
| Carlos Garcia-Parada | Chief Financial Officer · Jan 4, 2021 – Feb 14, 2022 · Past |
| Carlos Martin | Chief Commercial Officer · Nov 13, 2025 – Nov 5, 2026 · Past |
| Christopher James Stevens | Chief Operating Officer · Since at least Jul 7, 2025 |
| Dale Ritter | Vice President, Finance · Mar 22, 2016 – Sep 14, 2017 · Past |
| Devang Kantesaria | Director · Feb 17, 2015 – Feb 17, 2015 · Past |
| John Militello | See Remarks · Since at least Feb 17, 2023 |
| Joseph Manhede | Principal Accounting Officer · Since at least Jul 8, 2026 |
| Kinnari Patel | See Remarks · Jan 4, 2018 – May 20, 2025 · Past |
| Mark Andrew White | See Remarks · Apr 4, 2023 – Oct 31, 2024 · Past |
| Martin Wilson | General Counsel · Since at least May 16, 2025 |
| Paul G Howes | Director · Feb 17, 2015 – Jun 20, 2017 · Past |
| Peter Fong | Chairman of the Board · Since at least Sep 24, 2025 |
| Piratip Pratumsuwan | Director · Since at least Jan 27, 2025 |
| Sarbani Chaudhuri | See Remarks · Since at least Apr 7, 2025 |
Log in to ask 6ix AI your own questions about Rocket Pharmaceuticals, Inc.